Adaptive Cell Therapy is at the forefront of oncology, revolutionizing cancer care, particularly for lymphoma and multiple myeloma patients. However, the field faces significant barriers that limit accessibility for most patients. The main reasons for this are that existing cellular therapies are not effective in treating AML and the vast majority of solid tumors. Additionally, current cellular therapies are autologous, requiring complex, lengthy, and costly custom production for each patient.
Sakura Bio aims to break this barrier with Skill-T (Supper-Killer T) cells, an innovative off-the-shelf allogeneic T-cell product. This groundbreaking therapy offers an effective, safe, affordable, and accessible immunotherapy option, with a simple and fast manufacturing process, efficiently targeting both blood cancers and solid tumors.
CEO: Dikla Berko, PhD